Pimavanserin for the treatment of Parkinson's disease psychosis

Update on Typical and Atypical Antipsychotic Drugs

(2012) Herbert Y. Meltzer   Annual Review of Medicine

Psychiatric syndromes in Parkinsonʼs disease

(2012) Sergio E. Starkstein et al.   CURRENT OPINION IN PSYCHIATRY

Serotonin Receptors as Targets for Drugs Useful to Treat Psychosis and Cognitive Impairment in Schizophrenia

(2012) H. Y. Meltzer et al.   CURRENT PHARMACEUTICAL BIOTECHNOLOGY

Pimavanserin, a selective serotonin (5-HT)2A-inverse agonist, enhances the efficacy and safety of risperidone, 2mg/day, but does not enhance efficacy of haloperidol, 2mg/day: Comparison with reference dose risperidone, 6mg/day

(2012) Herbert Y. Meltzer et al.   SCHIZOPHRENIA RESEARCH

Pimavanserin, a 5-HT2A inverse agonist, reverses psychosis-like behaviors in a rodent model of Parkinsonʼs disease

(2011) Krista McFarland et al.   BEHAVIOURAL PHARMACOLOGY

Inverse agonism and its therapeutic significance

(2011) Gurudas Khilnani et al.   INDIAN JOURNAL OF PHARMACOLOGY

Parkinson's disease: The quintessential neuropsychiatric disorder

(2011) Daniel Weintraub et al.   MOVEMENT DISORDERS

Pimavanserin tartrate, a 5-HT2A receptor inverse agonist, increases slow wave sleep as measured by polysomnography in healthy adult volunteers

(2011) Sonia Ancoli-Israel et al.   SLEEP MEDICINE

A randomized controlled trial of quetiapine for psychosis in Parkinson’s disease

(2010) Paul Shotbolt   Neuropsychiatric Disease and Treatment

QUETIAPINE IMPROVES VISUAL HALLUCINATIONS IN PARKINSON DISEASE BUT NOT THROUGH NORMALIZATION OF SLEEP ARCHITECTURE: RESULTS FROM A DOUBLE-BLIND CLINICAL-POLYSOMNOGRAPHY STUDY

(2009) HUBERT H. FERNANDEZ et al.   INTERNATIONAL JOURNAL OF NEUROSCIENCE

Epidemiology of psychosis in Parkinson's disease

(2009) Gilles Fénelon et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Pimavanserin, a Serotonin2A Receptor Inverse Agonist, for the Treatment of Parkinson's Disease Psychosis

(2009) Herbert Y Meltzer et al.   NEUROPSYCHOPHARMACOLOGY

Non-motor symptoms in a prevalent population with Parkinson's disease in Tanzania

(2009) C.L. Dotchin et al.   PARKINSONISM & RELATED DISORDERS

5-HT2A Inverse-Agonists for the Treatment of Insomnia

(2008) Bradley Teegarden et al.   CURRENT TOPICS IN MEDICINAL CHEMISTRY

Pimavanserin tartrate: a 5-HT2A inverse agonist with potential for treating various neuropsychiatric disorders

(2008) Atheir Abbas et al.   EXPERT OPINION ON PHARMACOTHERAPY

A 5-HT2A receptor inverse agonist, ACP-103, reduces tremor in a rat model and levodopa-induced dyskinesias in a monkey model

(2008) K VANOVER et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR